Related Experiment Video

Updated: Jul 12, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 10, 2014

Protease inhibitor-associated hyperglycemia in Mexican patients with HIV infection

A Palma-Aguirre1, J Halabe-Cherem, H Nellen-Hummel

  • 1Unidad de Investigación Médica en Farmacología, México, D.F., Mexico. Apalma@chdr.nl

Archives of Medical Research
|April 18, 2000
PubMed
Abstract

Insights

Protease inhibitors for HIV are effective but may cause hyperglycemia and diabetes. Monitoring is crucial, especially in the Mexican population, to manage these risks.

Area of Science:

  • Infectious Diseases
  • Endocrinology
  • Pharmacology

Background:

  • Protease inhibitors have transformed HIV treatment.
  • The FDA has alerted physicians to potential hyperglycemia and diabetes risks associated with protease inhibitors.
  • These risks are based on limited physician reports.

Purpose of the Study:

  • To investigate the incidence of hyperglycemia in HIV patients receiving protease inhibitor therapy.
  • To assess the relationship between protease inhibitor use and the development of diabetes mellitus in a specific ethnic group.

Main Methods:

  • A cohort of 61 HIV-infected patients without pre-existing diabetes was studied.
  • Plasma glucose levels were monitored monthly for six months.
  • Basal glucose levels were recorded before initiating protease inhibitor therapy.

Main Results:

  • Four patients (6.55%) developed hyperglycemia while on saquinavir.
  • One patient with hyperglycemia had a family history of type II diabetes.
  • Hyperglycemia in affected patients was managed effectively with diet.

Conclusions:

  • The benefits of protease inhibitors in HIV treatment likely outweigh the risks.
  • Physicians should remain vigilant for hyperglycemia in Mexican patients on protease inhibitors.
  • Patients need to be aware of hyperglycemia and diabetes warning signs.

More Related Videos

Cellular Redox Profiling Using High-content Microscopy11:37

Cellular Redox Profiling Using High-content Microscopy

Published on: May 14, 2017

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Concept Videos

Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...